Cover Image
市場調查報告書

全球疫苗市場產品和開發平台分析

Product and Pipeline Analysis of the Global Vaccines Market

出版商 Frost & Sullivan 商品編碼 318254
出版日期 內容資訊 英文 145 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球疫苗市場產品和開發平台分析 Product and Pipeline Analysis of the Global Vaccines Market
出版日期: 2014年10月31日 內容資訊: 英文 145 Pages
簡介

疫苗是為了減少死亡率及罹患率,以預防傳染病為目的所施打的生技藥品。

本報告提供全球疫苗市場相關調查分析,提供您包含上市產品,臨床實驗中的產品,價值鏈,法規環境,主要的產品簡介等系統性資訊。

第1章 摘要整理

第2章 調查手法和範圍

第3章 簡介

第4章 市場背景

  • 實行技術
  • 法規核准流程
  • 全球法規當局的監視
  • 市場收益預測
  • 價值鏈分析
  • 波特的五力分析
  • 主要的差距
  • 疫苗的保存和物流
  • 疫苗的價格設定

第5章 競爭情形

  • 競爭情形概要
  • 產品銷售的時間軸
  • 專利到期
  • 細菌疫苗市場區隔:持續中/最近完成的臨床實驗
  • 病毒疫苗市場區隔:持續中/最近完成的臨床實驗
  • 癌症疫苗市場區隔:持續中/最近完成的臨床實驗

第6章 競爭情形:細菌疫苗

  • 細菌疫苗市場區隔概要
  • 主要的上市·開發中產品
  • 主要上市產品
  • 主要的階段3開發中產品
  • 主要的階段2開發中產品
  • 主要的階段1開發中產品

第7章 競爭情形:病毒疫苗

  • 病毒疫苗市場區隔概要
  • 主要的上市·階段3開發中產品
  • 主要的階段1·2開發中產品
  • 主要上市產品
  • 主要的階段3開發中產品
  • 主要的階段2開發中產品
  • 主要的階段1開發中產品

第8章 競爭情形:寄生蟲疫苗

  • 寄生蟲疫苗市場區隔概要
  • 主要的上市·開發中產品
  • 主要的階段3開發中產品
  • 主要的階段2開發中產品
  • 主要的階段1開發中產品

第9章 競爭情形:癌症疫苗

  • 癌症疫苗市場區隔概要
  • 主要的上市·開發中產品
  • 主要上市產品
  • 主要的階段3開發中產品
  • 主要的階段2開發中產品
  • 主要的階段1開發中產品

第10章 競爭情形:過敏疫苗

  • 癌症疫苗市場區隔概要
  • 主要的上市·開發中產品
  • 主要上市產品
  • 主要的階段3開發中產品
  • 主要的階段2開發中產品
  • 主要的階段1開發中產品

第11章 競爭情形:其他疫苗

  • 其他疫苗市場區隔概要
  • 主要的開發中產品
  • 主要的階段3開發中產品
  • 主要的階段2開發中產品
  • 主要的階段1開發中產品

第12章 細菌疫苗產品的儀表板

第13章 病毒疫苗產品的儀表板

第14章 寄生蟲疫苗產品的儀表板

第15章 癌症疫苗產品的儀表板

第16章 過敏疫苗產品的儀表板

第17章 其他疫苗產品的儀表板

第18章 主要活動的時間軸

第19章 結論

第20章 關於Frost&Sullivan

目錄
Product Code: MA4C-01-00-00-00

Expected Launches in the Areas of Cancer and Allergies Will Drive Growth

Vaccines represent a class of biologics that are administered to prevent infectious diseases to reduce mortality and morbidity. It is estimated that the introduction of vaccines has reduced the incidence of various diseases by greater than 90%. This study examines the global vaccines market, including marketed products and products under clinical development. It also presents an overview of the value chain and regulatory environment, and offers profiles of key marketed and pipeline products. The market is segmented into infectious disease vaccines, cancer vaccines, allergy vaccines, and others (e.g., vaccines for physiological disorders such as diabetes and Alzheimer's disease). The base year is 2013.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Executive Summary (continued)
  • 4. Executive Summary (continued)
  • 5. New Market Opportunities
  • 6. Recent Market Developments
  • 7. Recent Market Developments (continued)
  • 8. Companies to Watch
  • 9. Companies to Watch (continued)

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope
  • 2. Market Segmentation

3. INTRODUCTION

Introduction

  • 1. Introduction

4. MARKET BACKGROUND

Market Background

  • 1. Enabling Technologies
  • 2. Regulatory Approval Process
  • 3. Regulatory Approval Process (continued)
  • 4. Global Regulatory Oversight
  • 5. Regulatory Oversight (continued)
  • 6. Regulatory Oversight (continued)
  • 7. Market Revenue Forecast
  • 8. Value Chain Analysis
  • 9. Value Chain Analysis (continued)
  • 10. Value Chain Analysis (continued)
  • 11. Porter's 5 Forces Analysis
  • 12. Porter's 5 Forces Analysis (continued)
  • 13. Porter's 5 Forces Analysis (continued)
  • 14. Key Gaps
  • 15. Vaccine Storage and Logistics
  • 16. Vaccine Pricing
  • 17. Vaccine Pricing (continued)
  • 18. Vaccine Pricing (continued)

5. COMPETITIVE LANDSCAPE

Competitive Landscape

  • 1. Competitive Landscape Overview
  • 2. Product Launch Timeline
  • 3. Patent Expirations
  • 4. Bacterial Vaccines Segment-Major Ongoing/Recently Completed Clinical Trials
  • 5. Viral Vaccines Segment-Major Ongoing/Recently Completed Clinical Trials
  • 6. Viral Vaccines Segment-Major Ongoing/Recently Completed Clinical Trials (continued)
  • 7. Cancer Vaccines Segment-Major Ongoing/Recently Completed Clinical Trials
  • 8. Cancer Vaccines Segment-Major Ongoing/Recently Completed Clinical Trials (continued)

6. COMPETITIVE LANDSCAPE-BACTERIAL VACCINES

Competitive Landscape-Bacterial Vaccines

  • 1. Bacterial Vaccines Segment Overview
  • 2. Bacterial Vaccines Segment-Key Marketed and Pipeline Products
  • 3. Bacterial Vaccines Segment-Key Marketed Products
  • 4. Bacterial Vaccines Segment-Key Marketed Products(continued)
  • 5. Bacterial Vaccines Segment-Key Phase 3 Pipeline Products
  • 6. Bacterial Vaccines Segment-Key Phase 2 Pipeline Products
  • 7. Bacterial Vaccines Segment-Key Phase 2 Pipeline Products (continued)
  • 8. Bacterial Vaccines Segment-Key Phase 1 Pipeline Products
  • 9. Bacterial Vaccines Segment-Key Phase 1 Pipeline Products (continued)

7. COMPETITIVE LANDSCAPE-VIRAL VACCINES

Competitive Landscape-Viral Vaccines

  • 1. Viral Vaccines Segment Overview
  • 2. Viral Vaccines Segment-Key Marketed and Phase 3 Pipeline Products
  • 3. Viral Vaccines Segment-Key Phase 1 and 2 Pipeline Products
  • 4. Viral Vaccines Segment-Key Marketed Products
  • 5. Viral Vaccines Segment-Key Marketed Products (continued)
  • 6. Viral Vaccines Segment-Key Marketed Products (continued)
  • 7. Viral Vaccines Segment-Key Phase 3 Pipeline Products
  • 8. Viral Vaccines Segment-Key Phase 2 Pipeline Products
  • 9. Viral Vaccines Segment-Key Phase 2 Pipeline Products (continued)
  • 10. Viral Vaccines Segment-Key Phase 2 Pipeline Products (continued)
  • 11. Viral Vaccines Segment-Key Phase 1 Pipeline Products
  • 12. Viral Vaccines Segment-Key Phase 1 Pipeline Products (continued)

8. COMPETITIVE LANDSCAPE-PARASITIC VACCINES

Competitive Landscape-Parasitic Vaccines

  • 1. Parasitic Vaccines Segment Overview
  • 2. Parasitic Vaccines Segment-Key Marketed and Pipeline Products
  • 3. Parasitic Vaccines Segment-Key Phase 3 Pipeline Products
  • 4. Parasitic Vaccines Segment-Key Phase 2 Pipeline Products
  • 5. Parasitic Vaccines Segment-Key Phase 1 Pipeline Products

9. COMPETITIVE LANDSCAPE-CANCER VACCINES

Competitive Landscape-Cancer Vaccines

  • 1. Cancer Vaccines Segment Overview
  • 2. Cancer Vaccines Segment-Key Marketed and Pipeline Products
  • 3. Cancer Vaccines Segment-Key Marketed Products
  • 4. Cancer Vaccines Segment-Key Phase 3 Pipeline Products
  • 5. Cancer Vaccines Segment-Key Phase 2 Pipeline Products
  • 6. Cancer Vaccines Segment-Key Phase 2 Pipeline Products (continued)
  • 7. Cancer Vaccines Segment-Key Phase 1 Pipeline Products

10. COMPETITIVE LANDSCAPE-ALLERGY VACCINES

Competitive Landscape-Allergy Vaccines

  • 1. Allergy Vaccines Segment Overview
  • 2. Allergy Vaccines Segment-Key Marketed and Pipeline Products
  • 3. Allergy Vaccines Segment-Key Marketed Products
  • 4. Allergy Vaccines Segment-Key Phase 3 Pipeline Products
  • 5. Allergy Vaccines Segment-Key Phase 2 Pipeline Products
  • 6. Allergy Vaccines Segment-Key Phase 1 Pipeline Products

11. COMPETITIVE LANDSCAPE-OTHER VACCINES

Competitive Landscape-Other Vaccines

  • 1. Other Vaccines Segment Overview
  • 2. Other Vaccines Segment-Key Pipeline Products
  • 3. Other Vaccines Segment-Key Phase 3 Pipeline Products
  • 4. Other Vaccines Segment-Key Phase 2 Pipeline Products
  • 5. Other Vaccines Segment-Key Phase 1 Pipeline Products

12. BACTERIAL VACCINE PRODUCT DASHBOARD

Bacterial Vaccine Product Dashboard

  • 1. Product Dashboard-Prevnar 13 (Pfizer)
  • 2. Product Dashboard-Menveo (Novartis)
  • 3. Product Dashboard-PXVX0200 (PaxVax)
  • 4. Product Dashboard-RUTI Vaccine (Archivel Farma)
  • 5. Product Dashboard-V-7 Immunitor (Immunitor)

13. VIRAL VACCINE PRODUCT DASHBOARD

Viral Vaccine Product Dashboard

  • 1. Product Dashboard-Pediarix (GSK)
  • 2. Product Dashboard-Gardasil (Merck & Co.)
  • 3. Product Dashboard-Zostavax (Merck & Co. and Sanofi)
  • 4. Product Dashboard-Rotarix (GSK)
  • 5. Product Dashboard-Flucelvax (Novartis)
  • 6. Product Dashboard-Multimeric-001 (Biondvax)
  • 7. Product Dashboard-Vacc-4x (Bionor Pharma)
  • 8. Product Dashboard-PennavaxG (Inovio)

14. PARASITIC VACCINE PRODUCT DASHBOARD

Parasitic Vaccine Product Dashboard

  • 1. Product Dashboard-Mosquirix (GSK)

15. CANCER VACCINE PRODUCT DASHBOARD

Cancer Vaccine Product Dashboard

  • 1. Product Dashboard-Provenge (Dendreon)
  • 2. Product Dashboard-DCVax-Prostate (Northwest Biotherapeutics)
  • 3. Product Dashboard-AE37 (Antigen Express)
  • 4. Product Dashboard-OncoVAX (Vaccinogen)

16. ALLERGY VACCINE PRODUCT DASHBOARD

Allergy Vaccine Product Dashboard

  • 1. Product Dashboard-Oralair (Greer Laboratories)

17. OTHER VACCINE PRODUCTS DASHBOARD

Other Vaccine Products Dashboard

  • 1. Product Dashboard-NicVax (Nabi)
  • 2. Product Dashboard-AD02 (AFFiRiS)

18. TIMELINE OF KEY EVENTS

Timeline of Key Events

  • 1. Vaccines Market-Timeline of Key Events
  • 2. Vaccines Market-Timeline of Key Events (continued)
  • 3. Vaccines Market-Timeline of Key Events (continued)
  • 4. Vaccines Market-Timeline of Key Events (continued)

19. CONCLUSIONS

Conclusions

  • 1. Conclusions
  • 2. New Market Opportunities
  • 3. Legal Disclaimer

20. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top